Q-omics provides the consensus-scored OR10H4 profile across patient tissues and cancer cell-line models. OR10H4 expression is associated with patient survival in 8 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, OR10H4 is differentially expressed in 1, with the highest sampling consensus in BRCA. Additionally, OR10H4 RNA expression shows 5,619 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight ACC, BRCA, and STAD as cancer lineages where OR10H4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for OR10H4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes OR10H4 survival associations across molecular data types. OR10H4 RNA expression shows survival associations in the most cancer types (8), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible OR10H4 RNA expression–survival associations across cancer types. High OR10H4 expression shows unfavorable associations in ACC, COAD, SCLC, STAD, UCEC and SARC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for OR10H4 RNA expression.
This table summarizes OR10H4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for OR10H4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. OR10H4 shows lower tumor expression in BRCA. The BRCA box plot shows higher OR10H4 RNA expression in normal versus tumor tissue (log2 FC = −0.020, t-test p = .007).
This table shows molecular features associated with OR10H4 in patient tissues and cancer cell lines. In patient samples, OR10H4 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set. In cancer cell lines, OR10H4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and UPPER_AERODIGESTIVE_TRACT.
